Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)DivestmentsExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogen (NEOG) Gains from Sales and Divestitures (2022 - 2025)

Neogen's quarterly Gains from Sales and Divestitures came in at $374000.0 in Q2 2025, up 62.61% year-on-year from $230000.0 in Q2 2024, and up 62.61% quarter-over-quarter from $230000.0 in Q2 2024.

Neogen has reported Gains from Sales and Divestitures for 4 years, with the latest figure at $374000.0 in Q2 2025.

  • For the quarter ending Q2 2025, Gains from Sales and Divestitures rose 62.61% year-over-year to $374000.0; the trailing twelve-month figure through May 2025 stood at $374000.0 (up 62.61% YoY), and the FY2025 full-year result was $374000.0, up 62.61% from the prior year.
  • Gains from Sales and Divestitures for Q2 2025 stood at $374000.0, up from $230000.0 in the prior quarter.
  • The five-year high for Gains from Sales and Divestitures was $374000.0 in Q2 2025, with the low at $25000.0 in Q2 2022.
  • Average Gains from Sales and Divestitures over 4 years is $172250.0, with a median of $145000.0 recorded in 2023.
  • Year-over-year, Gains from Sales and Divestitures surged 283.33% in 2024 and jumped 62.61% in 2025.
  • Tracing NEOG's Gains from Sales and Divestitures over 4 years: stood at $25000.0 in 2022, then soared by 140.0% to $60000.0 in 2023, then surged by 283.33% to $230000.0 in 2024, then surged by 62.61% to $374000.0 in 2025.
  • The last three Gains from Sales and Divestitures figures came in at $374000.0 (Q2 2025), $230000.0 (Q2 2024), and $60000.0 (Q2 2023), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn
10 Neogen 1.94 Bn 1.78 Bn 99.00 Mn

Historic Data

Download Data 🔒
DateValue
May 31, 2025 374,000.00
May 31, 2025 374,000.00
May 31, 2024 230,000.00
May 31, 2024 230,000.00
May 31, 2023 60,000.00
May 31, 2023 60,000.00
May 31, 2022 25,000.00
May 31, 2022 25,000.00